Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

Dreger, 2014, Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?, Blood, 124, 3841, 10.1182/blood-2014-07-586826 Salles, 2011, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, Lancet, 377, 42, 10.1016/S0140-6736(10)62175-7 van Oers, 2010, Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study, J Clin Oncol, 28, 2853, 10.1200/JCO.2009.26.5827 Vidal, 2011, Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials, J Natl Cancer Inst, 103, 1799, 10.1093/jnci/djr418 Shanafelt, 2013, Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL), Blood, 121, 4137, 10.1182/blood-2012-12-470005 Maddocks, 2014, A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia, Leuk Res, 38, 1025, 10.1016/j.leukres.2014.05.011 Del Poeta, 2008, Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia, Cancer, 112, 119, 10.1002/cncr.23144 Bo, 2014, NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment, Ann Hematol, 93, 1765, 10.1007/s00277-014-2117-x Foà, 2014, Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients, Am J Hematol, 89, 480, 10.1002/ajh.23668 Abrisqueta, 2013, Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia, Blood, 122, 3951, 10.1182/blood-2013-05-502773 Kaufman, 2011, Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia, Med Oncol, 28, 532, 10.1007/s12032-010-9478-3 Schweighofer, 2009, Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG), Br J Haematol, 144, 95, 10.1111/j.1365-2141.2008.07394.x Huang, 2014, How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation, Med Oncol, 31, 104, 10.1007/s12032-014-0104-7 Teeling, 2006, The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20, J Immunol, 177, 362, 10.4049/jimmunol.177.1.362 Barth, 2012, Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma, Br J Haematol, 156, 490, 10.1111/j.1365-2141.2011.08966.x Rafiq, 2013, Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties, J Immunol, 190, 2702, 10.4049/jimmunol.1202588 Wierda, 2010, Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia, J Clin Oncol, 28, 1749, 10.1200/JCO.2009.25.3187 Hallek, 2008, Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, 111, 5446, 10.1182/blood-2007-06-093906 Rawstron, 2007, International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia, Leukemia, 21, 956, 10.1038/sj.leu.2404584 Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Norman, 2003, Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation, Med Care, 41, 582, 10.1097/01.MLR.0000062554.74615.4C Greil R, Obrtlikova P, Smolej L, et al. Rituximab maintenance after chemoimmunotherapy induction in 1st and 2nd line improves progression free survival: planned interim analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial. 56th ASH Annual Meeting and Exposition; San Fransisco, CA, USA; Dec 6–9, 2014. Abstract 642. Komarova, 2014, Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL), Proc Natl Acad Sci USA, 111, 13906, 10.1073/pnas.1409362111 Woyach, 2014, Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib, N Engl J Med, 370, 2286, 10.1056/NEJMoa1400029 Chang, 2013, Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL), Proc Am Soc Clin Oncol, 31